Tech Company Financing Transactions

VectorY Funding Round

On 11/14/2023, VectorY announced $140.8 million in Series A funding from EQT Life Sciences, Forbion Growth Opportunities Fund II and ALS Investment Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Science Park Matrix Innovation Center 408
Amsterdam, 1098 XH
NL

Phone

+31 (0)20 226 80 20

Website

www.vectorytx.com

Email Address

[email protected]

Overview

We are an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives. Antibody treatments have wide applicability in neurodegenerative diseases that are known to be complex and difficult to treat. Our cutting-edge vectorized antibody technology combines highly selective therapeutic antibodies with one-time AAV-based delivery to the CNS. We are advancing a development pipeline of potentially disease-modifying treatments for ALS, Huntington's, and Parkinson's disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Sander Deventer

        

Chief Financial Officer

Michael Wyzga

        

Chief Scientific Officer

Pavlina Konstantinova

        

Chief Technical Officer

Barbara Sanders

        

Browse more venture capital transactions:

Prev: 11/14/2023: Augmentus venture capital transaction
Next: 11/14/2023: Refine Intelligence venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary